Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/27/2026 | $3.50 | Outperform → Sector Perform | RBC Capital Mkts | |
| 11/24/2025 | Buy | Truist | ||
| 11/13/2025 | $7.00 | Outperform | Leerink Partners | |
| 10/20/2025 | $10.00 | Overweight | Wells Fargo | |
| 10/10/2025 | $9.00 | Outperform | Leerink Partners | |
| 7/16/2025 | $9.00 | Buy | H.C. Wainwright | |
| 4/10/2025 | $12.00 | Outperform | Mizuho | |
| 2/10/2025 | $11.00 | Outperform | Wedbush |
8-K - Pulmatrix, Inc. (0001574235) (Filer)
SCHEDULE 13G/A - MANNKIND CORP (0000899460) (Subject)
425 - Pulmatrix, Inc. (0001574235) (Subject)
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company$19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseaseFRAMINGHAM, Mass. and HOUSTON, March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definitive merger agreement under which Pulmatrix will acquire Eos (the "Merger"). Upon completion of the Merger, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1DData to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lu
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock. About MannKindMannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize t
RBC Capital Mkts downgraded Mannkind from Outperform to Sector Perform and set a new price target of $3.50
Truist initiated coverage of Mannkind with a rating of Buy
Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $7.00
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reporte
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay w
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring dataThis outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancementMannKind extends its sincere gratitude to the study participants, investigators, advisors, and clinical site teams for their invaluable contributions to the ICoN-1 studyMannKind will host a conference call today at 9:00 AM EST to discuss this update in mo
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)